Showing 5261-5270 of 6036 results for "".
- AMA Pushes for Federal Intervention to Reform Prior Authorizationhttps://modernod.com/news/ama-pushes-for-federal-intervention-to-reform-prior-authorization/2477934/Docs say health plans have made little progress toward streamlining prior authorization—despite pledging to do so 2 years ago, according to a FierceHealthcare report.
- Sight Sciences Names New Chief Operating Officer and General Counselhttps://modernod.com/news/sight-sciences-names-new-chief-operating-officer-and-general-counsel/2477930/Sight Sciences announced two key hires: Sam Park, joining as Chief Operating Officer, and Jeremy Hayden, who joins as General Counsel and Chief Compliance Officer. “We are excited to be able to add leaders with the outstanding track records of Sam and Jeremy as Sight Sciences continu
- Sanofi Sees Potential Approval of COVID-19 Vaccine in First Half of 2021https://modernod.com/news/sanofi-sees-potential-approval-of-covid-19-vaccine-in-first-half-of-2021/2477923/Sanofi said Tuesday that it expects potential approval of a COVID-19 vaccine being jointly developed with GlaxoSmithKline in the first half of next year, brought forward from an earlier estimate of the second half of 2021. A phase 1/2 study of the recombinant protein-based vaccine approach, whic
- UK to Test Weekly, Swabless COVID-19 Screening for Health Care Workers, Students and Morehttps://modernod.com/news/uk-to-test-weekly-swabless-covid-19-screening-for-health-care-workers-students-and-more/2477918/The UK government will begin testing a new, swabless coronavirus test, designed to be completed at home on a weekly basis by spitting into a collection tube, according to a FierceBiotech
- Viela Bio Announces FDA Approval of Uplinza (Inebilizumab) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/viela-bio-announces-fda-approval-of-uplinza-inebilizumab-for-the-treatment-of-neuromyelitis-optica-spectrum-disorder-nmosd/2477912/Viela Bio announced the FDA approval of Uplizna (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD). The monotherapy drug is the first and only B cell-depleting antibody approved for the disease. Uplizna is indicated for those who are
- Santen and Orbis International Join Forces to Expand Access to Training for Eye Care Professionals Through Telemedicine Platformhttps://modernod.com/news/santen-and-orbis-international-join-forces-to-expand-access-to-training-for-eye-care-professionals-through-telemedicine-platform/2477910/Santen Pharmaceutical and Orbis International announced a partnership to develop a suite of digital training tools that will continue to help eye care professionals around the world build their skills. Through the 3-year, global partnership, Orbis and Santen will create online courses, live surgi
- Fitbit Joins Growing List of Companies Offering Back-to-Work Health Screening Toolshttps://modernod.com/news/fitbit-joins-growing-list-of-companies-offering-back-to-work-health-screening-tools/2477908/Device maker Fitbit is the latest technology company to jump into the back-to-work business, according to a FierceHealthcare
- NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical for Ophthalmic Quinolone Antibiotichttps://modernod.com/news/ntc-grants-license-and-distribution-rights-in-israel-to-taro-pharmaceutical-for-ophthalmic-quinolone-antibiotic/2477905/NTC has granted exclusive license and distribution rights to one of its research and development products, a fixed combination in eye drops, in Israel to Taro Pharmaceutical Industries. The product combines a quinolone antibiotic with an anti-inflammatory steroid
- NYU Langone Names New Chair of Ophthalmologyhttps://modernod.com/news/nyu-langone-names-new-chair-of-ophthalmology/2477903/Kathryn A. Colby, MD, PhD, an internationally renowned physician–scientist, has been appointed chair of the Department of Ophthalmology at NYU Langone Health. She assumes her new post this fall. Dr. Colby is currently the Louis Block Professor and chair of the Department of Ophthalmology a
- Bionic Sight Doses First Patient in a Phase 1/2 Clinical Trial of a New Investigational Treatment for Retinitis Pigmentosahttps://modernod.com/news/bionic-sight-llc-doses-first-patient-in-a-phase-1-2-clinical-trial-of-a-new-investigational-treatment-for-blindness-caused-by-retinitis-pigmentosa/2477902/Bionic Sight announced that it has dosed the first patient in the company’s phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with retinitis pigmentosa. This is an important step toward bringing BS01 forward as a treatment to enable patients with retinal degenerative dise